GLP-1 receptor agonists show anti-inflammatory and neuroprotective effects in animal models of multiple sclerosis, delaying disease onset, reducing severity, and promoting nerve regeneration.
Delayed onset + increased myelinationGLP-1 agonists significantly delayed MS-like symptoms and increased nerve myelination in animal models of the disease
What the researchers found
The review synthesizes evidence showing multiple neuroprotective and anti-inflammatory effects of GLP-1 receptor agonists relevant to MS:
- In animal models of experimental autoimmune encephalopathy (the standard MS model), GLP-1 agonists significantly delayed symptom onset and reduced disease severity
- Treatment increased nerve myelination and brain weight in these models
- In nerve crush injury models, GLP-1 agonists significantly increased the rate and density of nerve regeneration compared to controls
- The mechanism likely involves GLP-1 receptors present on immune cells (macrophages, monocytes, lymphocytes), allowing the drugs to modulate inflammatory responses
The authors conclude that GLP-1 agonists show promise as both prophylactic and symptomatic treatments for MS.
Why it matters
Multiple sclerosis affects nearly 3 million people worldwide, and current treatments can have significant side effects. GLP-1 agonists are already FDA-approved, well-studied, and widely available — if their neuroprotective effects translate to humans, they could be rapidly repurposed for MS treatment with known safety profiles.
How the study worked
This is a narrative review synthesizing published preclinical studies on GLP-1 receptor agonists in animal models of multiple sclerosis (experimental autoimmune encephalopathy) and nerve injury. The authors surveyed evidence on anti-inflammatory mechanisms, neuroprotection, and nerve regeneration.
What this study cannot tell us
All evidence reviewed comes from animal models, not human clinical trials. The exact mechanisms by which GLP-1 agonists affect MS remain unclear. Whether the drug concentrations that reach the brain in humans would be sufficient for neuroprotection is unknown. MS is a complex disease with multiple subtypes, and animal models may not capture all aspects of human disease.
How to read the evidence
This is a narrative review of primarily preclinical (animal model) evidence. While the findings are consistent and promising, no human clinical trials for MS with GLP-1 agonists have been completed, limiting the evidence grade.
When this study was published
Published in 2024, this review captures growing interest in repurposing GLP-1 agonists for neurological conditions, a trend accelerated by the drugs' commercial success for diabetes and obesity.
The bigger picture
This review is part of a growing recognition that GLP-1 agonists have effects far beyond blood sugar and weight — including neuroprotection, anti-inflammation, and potential benefits in neurodegenerative diseases. Research is also exploring their use in Alzheimer's and Parkinson's disease, suggesting these peptide drugs may represent a new class of multi-purpose therapeutics.
Questions still open
- Are MS patients who happen to take GLP-1 agonists for diabetes experiencing slower disease progression?
- Which GLP-1 agonist has the best brain penetration for potential neurological applications?
- Would GLP-1 agonists work better as a preventive measure or as a treatment for active MS?
Common questions
Can I take Ozempic or Wegovy for multiple sclerosis?
How might GLP-1 drugs help with a nerve disease like MS?
Read the original research
The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Multiple Sclerosis: A Narrative Review.
Cureus, 16(8), e67232
Citation
Kaye, Alan D; Sala, Kelly R; Abbott, Brennan M; Dicke, Alexandra N; Johnson, Landyn D; Wilson, Parker A; Amarasinghe, Sam N; Singh, Naina; Ahmadzadeh, Shahab; Kaye, Adam M; Shekoohi, Sahar; Varrassi, Giustino. (2024). The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Multiple Sclerosis: A Narrative Review.. Cureus, 16(8), e67232. https://doi.org/10.7759/cureus.67232